Innovative Medicine
-
Study Observed Association between JANSSEN® CONNECT® Injection Centers and Increased Adherence to Healthcare Provider-Ordered Janssen Long-Acting Treatment for People with Schizophrenia
JANSSEN® CONNECT® program seeks to provide people living with schizophrenia information and assistance to support healthcare provider-ordered long-acting antipsychotic treatment -
Johnson & Johnson Announces New Grant to Harvard Medical School to Combat Drug-Resistant Tuberculosis
New collaboration will help address significant global unmet needs in pediatric drug-resistant tuberculosis (DR-TB) treatment and optimize use of existing DR-TB treatments -
-
New Data Show Once-Daily XARELTO® May Be an Alternative to Vitamin K Antagonists in Treating Atrial Fibrillation Patients Undergoing Elective Cardioversion
X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal -
Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO® in Addressing Critical Medical Needs
New Studies Grow XARELTO® Clinical Development Program to More Than 275,000 Patients -
Janssen Diagnostics Expands Research Portfolio to Include Next-Generation Sequencing
Enhanced Offering to Enable ‘Dynamic Monitoring’ in Cancer Research -
Janssen Affiliate Cilag GmbH International Acquires Covagen AG
Clinical Candidate COVA 322 and FynomAb® Technology Platform Further Strengthen Immunology Portfolio and Capabilities -
U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes
In Phase 3 studies, INVOKANA® plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone -
Janssen Launches Online Healthy Minds Video Series
Promotes Knowledge of Brain Disorders and Encourages Anti-Stigma Efforts